Vasopressin is not an inotrope. It is classified as a vasopressor, meaning it raises blood pressure by constricting blood vessels rather than by strengthening the heart’s contractions. In clinical practice, vasopressin is used to increase blood pressure in shock states, and major guidelines list it alongside other vasopressors, not alongside inotropes like dobutamine or milrinone.
That said, the picture is more nuanced than a simple “no.” Lab studies show vasopressin can have a modest effect on heart muscle contractility at certain concentrations, and ongoing clinical trials are actively comparing its cardiac effects to those of norepinephrine. Here’s what that means in practical terms.
What Makes a Drug an Inotrope vs. a Vasopressor
The distinction comes down to where the drug acts and what it changes. Inotropes increase the force of heart muscle contractions, which boosts cardiac output, the volume of blood the heart pumps per minute. Vasopressors constrict blood vessels, which raises systemic vascular resistance and, in turn, mean arterial pressure. Both approaches can improve blood flow to organs, but they accomplish it through fundamentally different mechanisms.
Some drugs blur the line. Norepinephrine, for instance, is primarily a vasopressor but also has inotropic properties because it stimulates receptors on heart muscle cells. Vasopressin, by contrast, works almost exclusively on the vascular side. It binds to V1 receptors on smooth muscle in blood vessel walls, causing them to tighten, and to V2 receptors in the kidneys, where it promotes water retention. Standard pharmacology references describe it as having no inotropic or chronotropic (heart rate) effects at clinical doses.
The Lab Evidence for a Weak Inotropic Effect
Isolated heart experiments tell a slightly different story. In one well-known study using a Langendorff preparation (an isolated heart kept beating outside the body), vasopressin at concentrations around 50 picograms per milliliter increased the peak rate of pressure rise in the ventricle by about 44%. That’s a meaningful boost in contractile force, and it occurred at concentrations similar to what circulates in the blood during certain stress states.
However, the relationship was not straightforward. At higher concentrations (400 to 500 picograms per milliliter), contractility actually dropped about 34% below baseline. This biphasic pattern, a small boost at low doses and a decline at high doses, is one reason vasopressin isn’t considered a reliable inotrope. The positive effect was entirely blocked by a V1 receptor antagonist, confirming it works through the same receptor responsible for vasoconstriction. A V2-specific drug had no effect on the heart at all.
So vasopressin can nudge contractility upward under controlled lab conditions, but the effect is dose-dependent, narrow in range, and far weaker than what true inotropes deliver.
What Happens to Cardiac Output in Real Patients
In clinical settings, vasopressin’s effect on cardiac output is largely neutral. A review of studies in patients with vasodilatory shock found that low-dose vasopressin (around 0.04 units per minute) maintained cardiac output without causing a substantial decline. In 41 patients with severe shock after cardiac surgery, vasopressin infusion kept cardiac index and stroke volume stable even as the need for other inotropic drugs decreased.
That stability is notable because vasopressin significantly increases afterload, the resistance the heart must pump against. A drug that raises afterload without any contractile support would normally cause cardiac output to fall. The fact that it doesn’t may reflect a subtle inotropic contribution, or it may simply mean the improved blood pressure restores adequate filling of the heart. Researchers are still sorting this out. A randomized clinical trial currently underway is directly comparing vasopressin’s cardiac effects to those of norepinephrine in post-cardiac surgery patients, using echocardiographic measurements to settle the question more definitively.
How Vasopressin Affects Heart Rate
One distinctive feature of vasopressin is that it tends to slow the heart rate. This happens through two pathways. First, the rise in blood pressure triggers a normal baroreflex response: the body senses higher pressure and dials back heart rate to compensate. Second, vasopressin appears to enhance this slowing effect through a direct action on specific brain structures involved in heart rate regulation. The result is a modest bradycardia that sets vasopressin apart from catecholamine vasopressors, which typically increase heart rate.
For patients in shock whose hearts are already racing from high doses of catecholamines, this heart rate reduction can actually be beneficial. A slower heart rate gives the ventricles more time to fill between beats, which can improve the efficiency of each contraction.
Where Vasopressin Fits in Shock Treatment
The 2021 Surviving Sepsis Campaign guidelines recommend norepinephrine as the first-line vasopressor for septic shock. Vasopressin is recommended as an add-on when norepinephrine alone isn’t maintaining adequate blood pressure, typically when the norepinephrine dose reaches 0.25 to 0.5 micrograms per kilogram per minute. Unlike most vasopressors, vasopressin is usually given at a fixed dose of 0.03 units per minute rather than being titrated up and down based on response.
Its role is specifically as a vasopressor supplement. When patients need help with cardiac contractility, clinicians turn to dedicated inotropes like dobutamine (which stimulates heart muscle directly) or milrinone (which works by increasing levels of a signaling molecule inside heart cells). These drugs reliably increase cardiac output in ways vasopressin does not.
Risks to the Heart at Higher Doses
Vasopressin constricts coronary arteries through the same V1 receptor mechanism it uses on other blood vessels. At higher infusion rates, this can reduce blood flow to the heart muscle even though overall blood pressure is higher. In animal studies, vasopressin dose-dependently reduced coronary blood flow after episodes of cardiac ischemia, which coincided with impaired relaxation of the left ventricle between beats.
In a mouse model of heart attack, a three-day vasopressin infusion decreased the heart’s ejection fraction and increased mortality compared to dobutamine. This is essentially the opposite of an inotropic effect: rather than supporting the heart, vasopressin at sustained or elevated doses can actively impair cardiac function by starving it of blood supply. This risk is particularly relevant for patients with existing coronary artery disease or heart failure, where even modest reductions in coronary flow can tip the balance.
One interesting vascular distinction: vasopressin raises systemic vascular resistance in a dose-dependent, linear fashion but does not appear to affect pulmonary vascular resistance. This selective action on the systemic circulation can be advantageous in certain clinical scenarios where elevated pressure in the lung’s blood vessels would be harmful.